Published: September 18, 2015
Source: Corporate News Center, UTop Pharma
On the eve of the company’s tenth anniversary, UTop Pharma’s News Center sat down with our founder and chairman, Dr. Zhang, for an in-depth interview. He recounts the company’s difficult early years, explains how a technology-first approach enabled UTop Pharma to survive and grow amid fierce price competition in China’s API market, and outlines the strategic shift toward therapeutic peptide intermediates that will shape the company’s next phase.
“Our first lab had only two freeze-dryers, a pressure reactor and three researchers,” Dr. Zhang recalled with a wry smile. “There was nothing glamorous about it — it was pure idealism.”
Between 2006 and 2010, the Chinese API sector was swept by brutal price competition, and many companies survived by undercutting each other on price. UTop Pharma chose a different route: build on technology and compete on quality.
The company was among the first domestically to combine solid-phase peptide synthesis with precision lyophilization, and it established an independent Quality Management System (QMS). Passing the European CEP certification in 2010 marked the moment UTop Pharma entered the international pharmaceutical supply chain.
“That moment proved that Chinese R&D and manufacturing can meet global standards,” Dr. Zhang said firmly.
A recurring theme in the interview was the phrase “technical premium.”
“When others chased volume through low prices, we won customers with data, stability and consistency,” Dr. Zhang noted.
From 2012 to 2014, the company significantly increased R&D investment, refined freeze-drying control curves, improved peptide activity retention and achieved standardized production of lyophilized intermediates. The results: UTop Pharma not only consolidated its domestic position but also became a trusted supplier to many European, Japanese and Korean pharmaceutical companies.
“We understand that short-term margins don’t define success. Only ownership of core technology lets you stay resilient through market cycles,” Dr. Zhang said.
Asked about future directions, Dr. Zhang revealed that UTop Pharma has already begun strategic initiatives in therapeutic peptide intermediates.
“Our aim is to move beyond raw materials toward therapeutic peptide intermediates that can enter clinical development,” he explained.
Current project pipelines include:
Process development for GLP-1 class diabetes peptide intermediates;
Synthesis and lyophilization validation for dual-acting GIP/GLP-1 peptides;
Stability evaluation and industrial pre-research for anti-obesity peptide fragments.
Advancing these projects signals UTop Pharma’s transition from a supplier of high-quality raw materials to a platform capable of supporting drug development and higher value-added offerings.
Reflecting on ten years of growth, Dr. Zhang identified “long-termism” as the company’s central guiding principle.
“We’re not in the business of quick wins,” he said. “We’re building a scientific enterprise that requires time and patience.”
Over the next five years, the company will concentrate on three strategic priorities:
Strengthening the foundation: upgrade freeze-drying and purification automation and advance toward intelligent manufacturing;
Driving breakthroughs: deepen process innovations and secure IP for therapeutic peptide intermediates;
Expanding collaborations: partner with global pharma and academic institutions to accelerate international applications of China’s peptide technologies.
From a compact lab of less than a hundred square meters to an internationally certified enterprise with a global client network, UTop Pharma’s trajectory reflects the broader rise of China’s peptide industry.
In closing, Dr. Zhang said:
“A decade of honing one’s craft. True innovation isn’t imitation — it’s delivering Chinese solutions the world can rely on.”
UTop Pharma’s story continues.
Issued by: Corporate News Center
Editor: Corporate Branding Department
Date: September 18, 2015
